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Abstract
Quetiapine is an established drug for treatment of schizophrenia, bipolar disorder, and major depressive
disorder. While initially manufactured as an immediate-release (IR) formulation, an extended-release (XR)
formulation has recently been introduced. Pharmacokinetic studies show that quetiapine XR provides a
lower peak and more stable plasma concentration than the IR formulation. This study investigated if
the pharmacokinetic diﬀerences translate into diﬀerent time curves for central D2 dopamine receptor
occupancy. Eleven control subjects were examined with positron emission tomography (PET) and the
radioligand [
11C]raclopride. Eight subjects underwent all of the scheduled PET measurements. After
baseline examination, quetiapine XR was administered once-daily for 8 d titrated to 300 mg/d on days
5–8, followed by 300 mg/d quetiapine IR on days 9–12. PET measurements were repeated after the last
doses of quetiapine XR and IR at predicted times of peak and trough plasma concentrations. Striatal
D2 receptor occupancy was calculated using the simpliﬁed reference tissue model. Peak D2 receptor
occupancy was signiﬁcantly higher with quetiapine IR than XR in all subjects (50¡4% and 32¡11%,
respectively), consistent with lower peak plasma concentrations for the XR formulation. Trough D2
receptor occupancy was similarly low for both formulations (IR 7¡7%, XR 8¡6%). The lower peak
receptor occupancy associated with quetiapine XR may explain observed pharmacodynamic diﬀerences
between the formulations. Assuming that our ﬁndings in control subjects are valid for patients with
schizophrenia, the study supports the view that quetiapine, like the prototype atypical antipsychotic
clozapine, may show antipsychotic eﬀect at lower D2 receptor occupancy than typical antipsychotics.
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Introduction
Quetiapine is an atypical antipsychotic drug with
eﬃcacy demonstrated in clinical trials for the treat-
ment of schizophrenia, bipolar disorder, major de-
pressive disorder, and generalized anxiety disorder.
The clinical eﬀects are thought to be mediated by both
quetiapine and its main active human metabolite,
norquetiapine (Jensen et al. 2008). Quetiapine in its
original immediate-release (IR) formulation has a
short half-life (7 h) (Nemeroﬀ et al. 2002) and twice-
daily administration is recommended for the treat-
ment of schizophrenia and bipolar mania. To allow for
once-daily dosing, an extended-release (XR) formu-
lation has more recently been developed. Pharmaco-
kinetic studies have shown that, when given in
equivalent daily doses, the exposure in terms of area
under the curve (AUC) of the two compounds is
comparable.WhereastheXRformulation hasaslightly
lower peak plasma concentration (Cmax) than the
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ARTICLEIR formulation, it has a longer half-life (Figueroa et al.
2009).
To explore if there may be clinically important
pharmacodynamic diﬀerences between the two for-
mulations, it is of interest to establish if the diﬀerence
in pharmacokinetic proﬁle translates into diﬀerent
brain exposure and time-course of central receptor
occupancy. Positron emission tomography (PET)
studies of D2 dopamine receptor occupancy have
been well validated and demonstrated to have high
test–retest reproducibility (Nyberg et al. 1996), with D2
receptor occupancy showing a curvilinear relationship
with plasma drug concentrations. In patients treated
with quetiapine, PET studies have conﬁrmed occu-
pancy of the D2 receptor in the human brain. A marked
ﬂuctuation in D2 receptor occupancy during a dosing
interval has been shown in patients treated with
quetiapine IR at clinically relevant doses. Several
studies have reported moderate D2 receptor occu-
pancy (range 29–74%) at peak plasma levels, whereas
D2 receptor occupancy has been low or undetectable at
trough plasma levels (Gefvert et al. 1998; Kapur et al.
2000b; Mamo et al. 2008; Tauscher-Wisniewski et al.
2002). To date, quetiapine in the new XR formulation
has been examined in a single study (Mamo et al.
2008). In the cross-over study by Mamo and colleagues
12 patients with schizophrenia or schizoaﬀective dis-
order were assigned to one of three dose groups of
quetiapine (300, 600 or 800 mg/d). D2 occupancy was
compared at estimated times of peak and trough
plasma concentrations (Tmax and Tmin, respectively) of
equivalent daily doses of quetiapine XR and IR. There
was no statistically signiﬁcant diﬀerence in D2 receptor
occupancy between the formulations. However, the
study cannot be viewed as conclusive, since the lack of
a reported diﬀerence could be due to a large spread in
plasma concentrations and the small sample size in
each dose group (n=4). Moreover, the PET measure-
ments at expected IR peak were performed 1 h post-
administration and the Tmax of the IR formulation
has been reported to be 2 h (Figueroa et al. 2009).
Consequently, the D2 occupancy at IR peak in this
study might have been underestimated, as plasma
concentrations were not measured throughout the
dosing interval to conﬁrm that PET measurements
were performed at true peak concentration.
The primary aim of the present study was to com-
pare striatal D2 receptor occupancy with quetiapine
IR and XR in equal doses. A secondary purpose was
to examine the temporal relationship between the
plasma concentration of quetiapine and D2 receptor
occupancy. Eleven control subjects were examined
with PET and the radioligand [
11C]raclopride, before
and after treatment with 300 mg/d quetiapine XR and
IR, respectively. The D2 receptor occupancy values of
the present study are discussed in relation to literature
values for classical (typical) and atypical antipsychotic
drugs.
Method
Study design
The study was conducted as a research collaboration
between AstraZeneca, So ¨derta ¨lje, Sweden and the
Department of Clinical Neuroscience, Karolinska
Institutet, Stockholm, Sweden, and was approved by
the local Ethics and Radiation Safety Committees and
the Medical Products Agency in Sweden. The study
was designed as an open label, one-sequence cross-
over study, where each subject was his own control.
Study subjects
Eleven males aged between 21 and 29 yr (25¡2.5,
mean¡S.D.) were recruited from an AstraZeneca
database of subjects who expressed an interest in
participating in clinical studies. The subjects were
healthy according to medical history including psy-
chiatric symptoms and physical examination includ-
ing ECG, routine blood tests, and magnetic resonance
imaging (MRI) examination of the brain. A negative
urine drug screen was required for inclusion. No pre-
scribed drugs were allowed from 7 d before the ﬁrst
PET measurement and throughout the study. The use
of nicotine products was forbidden and caﬀeine intake
was restricted to a maximum of ﬁve cups per day.
The intake of these substances was monitored at an
AstraZeneca study unit, where subjects were super-
vised throughout the study period. All subjects gave
verbal and written consent after receiving a descrip-
tion of the study.
Administration of study drug and PET measurement
schedule
Quetiapine was administered orally, once-daily, in the
morning for 12 d. After 4 d of dose titration of quetia-
pine XR from 50 mg up to 300 mg, each subject re-
ceived 300 mg/d quetiapine XR for 4 d. Treatment
was then directly switched to 300 mg/d quetiapine IR
for 4 d.
Each subject participated in ﬁve PET measurements
in total. The measurements were performed at drug-
free conditions (baseline), at expected maximum
plasma concentration (Cmax) of quetiapine – which has
been reported to be at 2 h after the quetiapine IR dose
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at trough plasma concentration (Cmin). The PET
measurements at Cmax were performed on the fourth
day of administration of XR and IR, respectively,
whereas the measurements at Cmin were performed on
the morning after the last dose of each formulation.
Determination of plasma concentrations
Blood samples for determination of plasma concen-
trations of quetiapine and norquetiapine were col-
lected on the last day of treatment with the respective
formulations. For quetiapine XR, samples were drawn
pre-dose and at 0.5, 1, 2, 3, 4, 5, 5.5, 6, 8, 12, 24 and
25 h post-dose. For quetiapine IR, samples were
obtained pre-dose and at 0.5, 1, 1.5, 2, 2.5, 5, 11,
24 and 25 h post-dose. The diﬀerences in sampling
times for the two formulations were to allow for
dense sampling at expected Tmax. The samples were
analysed by BASi (Bioanalytical Systems Inc., USA)
by a liquid chromatography–tandem mass spectro-
metry (LC–MS/MS) method described in detail
elsewhere (Davis et al. 2010). The lower limit of
quantiﬁcation is <0.70 ng/ml (corresponding to
<1.8 nmol/l quetiapine) (Davis et al. 2010).
MRI and PET measurements
MRI T1-weighted images were acquired using a 1.5 T
GE Signa system (GE Medical Systems, USA). PET
examinations were performed using high-resolution
research tomography (HRRT; Siemens Molecular
Imaging, USA) with a spatial resolution of y1.5 mm
full-width-half-maximum (FWHM) (Varrone et al.
2009). A plastic helmet made individually for each
subject was used during each PET examination in
order to minimize head movements and to ensure
maintenance of the same head position in all experi-
ments.
[
11C]raclopride was prepared by methylation of the
corresponding desmethyl precursor using [
11C]methyl
triﬂate, as described previously (Langer et al. 1999).
At each examination, a saline solution containing
[
11C]raclopride with a radioactivity of 201–236 MBq
was injected in the antecubital vein as a bolus over 2 s.
The speciﬁc radioactivity at the time of injection
exceeded 1900 Ci/mmol and the injected ligand mass
was on all occasions <5 mg. This low mass does not
cause any substantial mass eﬀect of the ligand (Farde
et al. 1995). Radioactivity in the brain was measured
continuously over 63 min. The radioactivity from each
PET measurement was reconstructed in a series of
time-frames consisting of four 15-s, four 30-s, six
1-min, six 3-min and six 6-min frames.
Regions of interest (ROIs)
The MR images were realigned to the anterior–
posterior commissure plane. ROIs were manually de-
lineated on the realigned MR images for each subject
using software originally developed for the Human
Brain Atlas (Roland et al. 1994). Left and right puta-
mina were drawn on 6–8 (number depending on
individual anatomy) sagittal sections of the brain in
concordance with the anatomical limits. The cerebel-
lum was depicted on six adjacent central horizontal
sections. MR images were co-registered to averaged
PET images using statistical parametric mapping
software (SPM5, Wellcome Department of Cognitive
Neuroscience, UK). ROIs were then transferred to the
series of PET images to generate time–activity curves.
Calculation of binding potential (BP) and
D2 receptor occupancy
The BP in each PET measurement was calculated
using the simpliﬁed reference tissue model, with the
putamen as ROI and the cerebellum as reference re-
gion (Lammertsma & Hume, 1996). BP refers in this
context to BPND, which represents the ratio at equilib-
rium between the concentration of speciﬁcally bound
radioligand and that of the non-displaceable radio-
ligand in tissue (Innis et al. 2007).
The D2 receptor occupancy at peak and trough
concentration was calculated for each subject accord-
ing to the equation:
Occ=
BPbaselinexBPdrug
BPbaseline
r100, (1)
where Occ is the D2 receptor occupancy, BPbaseline is
the BP in the drug-free state, and BPdrug is the BP
measured at the respective time-points (peak and
trough) of drug treatment.
Calculation of apparent inhibition constant (Ki,app)
When assuming a linear relationship between drug
concentration in brain and drug concentration in
plasma, the relationship between D2 receptor occu-
pancy and plasma drug concentration can be de-
scribed by a curvilinear function according to the
expression:
Occ=
Occmax  Cp
Ki,app+Cp
, (2)
where Occmax is the maximal D2 receptor occupancy
induced by the drug and Cp is the plasma concen-
tration of the drug (Karlsson et al. 1995). Ki,app is an
aﬃnity constant corresponding to the drug plasma
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ceptors. D2 receptor occupancy values were plotted vs.
the corresponding plasma concentrations of quetia-
pine at the PET measurements. From the measured
values of occupancy and concentration, Ki,app was
determined by ﬁtting equation (2) to experimental
data using a nonlinear least-squares minimization
procedure. Occmax was ﬁxed to 100%, as it has been
previously demonstrated that 100% D2 receptor occu-
pancy is approached for [
11C]raclopride binding dur-
ing treatment with high doses of antipsychotic drugs
(Nyberg et al. 1998).
The ‘active moiety’
To allow comparisons with previous studies of D2
receptor occupancy after quetiapine treatment, the
initial calculation of Ki,app and the estimated time
curve for D2 receptor occupancy were based on the
plasma concentration values for quetiapine only. The
aﬃnity of the main metabolite, norquetiapine, for
the D2 receptor in vitro is of the same order as that
for quetiapine (Jensen et al. 2008). Assuming similar
aﬃnity and similar passage across the blood–brain
barrier in human subjects in vivo, the plasma concen-
tration values of quetiapine and norquetiapine were
summed to obtain a value for the ‘active moiety’. This
approach has previously been applied for risperidone
and its active metabolite, 9-OH risperidone (Cohen,
1994; Nyberg et al. 1993, 1999). In the calculation of
Ki,app, the explanatory power of the active moiety was
compared to quetiapine alone.
Estimation of the time curve for D2 receptor
occupancy during a dosing interval
To obtain a time curve for D2 receptor occupancy
throughout a dosing interval, the calculated Ki,app was
entered in equation (2) together with the mean plasma
concentration of quetiapine at each time-point. To
enable comparisons between the two formulations,
results were plotted separately for quetiapine XR
and IR.
Statistics
A two-tailed, two-sample t test was used to compare
the mean plasma concentrations achieved at peak
and trough. The same test was used to compare mean
D2 receptor occupancy with quetiapine IR and XR at
Cmax and Cmin. Neuroreceptor occupancy is not
normally distributed, due to the curvilinear relation-
ship between plasma concentration and occupancy,
and occupancy values can thus not be expected to be
normally distributed. However, at low concentrations,
the curve is approximately linear, which may allow
the use of a parametric test. In the present study, the
maximal mean D2 receptor occupancy measured at
peak was 59% and therefore the t test was also applied
to test diﬀerences at peak occupancies.
To ensure that quetiapine plasma concentration at
Tmax was not signiﬁcantly diﬀerent from quetiapine
plasma concentration during peak PET measure-
ments, the t test was also applied to compare mean
Cmax with mean concentration during peak PET
(Cav,PET,peak) for the respective formulations.
The statistical analysis was performed using SAS
statistical software JMP 8 (SAS Institute, USA).
Results
Of the 11 subjects enrolled in the study, eight under-
went all of the scheduled PET examinations according
to protocol. One subject discontinued before the fourth
PET measurement due to an adverse event (panic
attack, anxiety), and PET measurements and plasma
concentrations during treatment with the IR formu-
lation were therefore not obtained from this subject.
Due to synthesis failure of the radioligand, PET at XR
trough was not performed for one subject and PET at
IR peak was delayed 3.5 h for another subject. D2 re-
ceptor occupancy and plasma concentration values
from the delayed PET measurement were not included
in the analysis, as the timing of this measurement did
not correspond to the time of peak concentration.
Plasma concentrations
The plasma concentrations of quetiapine were
maximal at about 1.7 h after treatment with the
IR formulation and about 5 h after administration
of the XR formulation (Table 1, Fig. 1). Cmax for
quetiapine (mean¡S.D.) was 1850¡820 nmol/l and
894¡380 nmol/l for the IR and XR formulations,
respectively. The diﬀerence between formulations was
statistically signiﬁcant (d.f.=11.0, t=3.18, p<0.01).
At Tmax, the concentration of norquetiapine was
624¡100 nmol/l for IR and 346¡110 nmol/l for XR
(d.f.=17.0, t=5.55, p<0.0001).
For both formulations, the mean trough concentra-
tions of quetiapine during PET were signiﬁcantly
lower than the mean peak concentrations (IR:
d.f.=8.0, t=6.66, p=0.0002; XR: d.f.=9.2, t=6.82,
p<0.0001) (Fig. 1). Concentrations of quetiapine were
20.3¡7.8 nmol/l for IR and 69.9¡40 nmol/l for
XR during the second (trough) PET measurement.
The diﬀerence was statistically signiﬁcant (d.f.=9.7,
1360 M. Nord et al.t=3.82, p<0.005). Trough concentrations of norque-
tiapine were 111¡42 and 141¡57 nmol/l for IR and
XR, respectively. This diﬀerence was not statistically
signiﬁcant (d.f.=16.4, t=1.32, p=0.2).
D2 receptor occupancy
The PET measurements were performed close to
the observed peak concentrations of quetiapine and
norquetiapine, respectively. The time diﬀerence be-
tween the start time of the PET peak measurements
and Tmax of quetiapine were: IR (0.14¡0.43 h, range
x0.55 to 0.9) and XR (0.12¡2.6 h, range x6.76 to 2.24).
Thus, a larger range was noted for the XR formulation,
but the more blunted plasma concentration curve
with this formulation makes the timing of the PET
measurement less sensitive to deviations from Tmax.
The diﬀerence between quetiapine Cmax and the
plasma concentration measured during the peak PET
measurements (Cav,PET,peak) was not statistically sig-
niﬁcant for either formulation (IR: Cmax 1850¡820 vs.
Cav,PET,peak 1460¡510, d.f.=13.3, t=1.20, p=0.25; XR:
Cmax 894¡380 vs. Cav,PET,peak 719¡310, d.f.=17.2,
t=1.13, p=0.27). In all subjects, D2 receptor occupancy
was higher at IR peak compared to XR peak (Figs 2
and 3). The mean D2 receptor occupancy in the
putamen at peak concentration was 50¡4% for que-
tiapine IR (n=9) and 32¡11% for XR (n=11).
The diﬀerence was statistically signiﬁcant (d.f.=13.5,
t=4.89, p=0.0003). There was no signiﬁcant diﬀerence
in D2 receptor occupancy at trough levels between
the two formulations [IR 7¡7% (n=10), XR 8¡6%
(n=10); d.f.=17.6, t=0.41, p=0.7]. In two subjects,
trough occupancy even reached negative values
(x1% at XR trough for one subject and x3% at
IR trough for another subject). However, this minor
negativity was within the range for test–retest re-
liability.
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Fig. 1. Arithmetic mean plasma concentration of quetiapine and norquetiapine during quetiapine IR (left) and XR (right)
administration.
Table 1. Summary statistics of pharmacokinetic parameters of quetiapine and norquetiapine (PK analysis set)
Analyte Treatment N
Tmax (h)
Mean (S.D.)
Cmax (nmol/l)
Mean (S.D.)
AUC, 0–24
(h per nmol/l)
Mean (S.D.)
Cav,PET,peak
(nmol/l)
Mean (S.D.)
Cav,PET,trough
(nmol/l)
Mean (S.D.)
Quetiapine XR 10 5 (2.6) 894 (380) 8770 (3700) 719 (310) 69.9 (40)
IR 9 1.7 (0.7) 1850 (820) 8130 (2700) 1460 (510) 20.3 (7.8)
Norquetiapine XR 10 6 (3.3) 346 (110) 5740 (2100) 290 (120) 141 (57)
IR 9 2.1 (0.5) 624 (100) 6100 (1400) 554 (91) 111 (42)
Tmax, Time of peak plasma concentration; Cmax, peak plasma concentration; AUC, area under the curve; Cav,PET,peak, average
concentration of drug in plasma during PET examination at expected peak; Cav,PET,trough, average concentration of drug in
plasma during PET examination at expected trough.
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When using all PET measurements and the concen-
tration of quetiapine measured after administration
of IR and XR together, Ki,app was calculated to be
1369 nmol/l (Fig. 4). Ki,app calculated for quetiapine
IR only was 1373 nmol/l and for XR only
was 1365 nmol/l. Assuming that quetiapine and
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Fig. 2. Parametric horizontal PET images through the caudate putamen level showing the binding potential after intravenous
injection of [
11C]raclopride in a human subject at baseline conditions and after administration of quetiapine IR and XR,
respectively.
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receptor, the sum of the two concentrations was used
as an estimate of the active moiety. Ki,app calculated
for the active moiety using measurements for both
formulations was 2004 nmol/l, and Ki,app calculated
for IR and XR separately was 1968 nmol/l and
2041 nmol/l, respectively. The explanatory value of
quetiapine and norquetiapine alone or in combination
(interaction model) was also tested using nonlinear
mixed-eﬀects modelling. Goodness of ﬁt was not
improved using the interaction model (results not
shown).
The mean peak D2 receptor occupancy measured
after treatment with 300 mg of the XR formulation was
32% (range 13–45%). As the relationship between
dose and plasma concentration of quetiapine is linear
(DeVane & Nemeroﬀ, 2001), it is possible to use
equation (2) (see Methods section) to predict the dose
required to occupy 50% of the receptor. The calculated
Ki,app value corresponded to a dose of 638 mg at
steady state following once-daily dosing. For the IR
formulation, the mean peak D2 receptor occupancy
measured was 50%, thus corresponding to the ad-
ministered dose of 300 mg at steady state following
once-daily dosing.
Estimated D2 receptor occupancy over time
The time curve for estimated D2 receptor occupancy
during a dosing interval was calculated for both for-
mulations using equation (2) (Fig. 5). After adminis-
tration of quetiapine IR, a high and transient peak
D2 receptor occupancy was reached within 2 h, after
which D2 receptor occupancy slowly declined. For the
XR formulation, peak D2 receptor occupancy was less
pronounced and remained at a higher level compared
to IR.
Discussion
In the present PET study, we compared the D2 dopa-
mine receptor occupancy obtained after adminis-
tration of 300 mg quetiapine XR and IR once-daily at
steady-state conditions. Peak D2 receptor occupancy
was signiﬁcantly higher (p=0.0003) with the IR
formulation (Fig. 3), whereas there was no signiﬁcant
diﬀerence in trough D2 receptor occupancy between
quetiapine IR (7¡7%) and XR (8¡6%). The study
conﬁrms that the previously reported pharmaco-
kinetic diﬀerences between the two formulations
(Figueroa et al. 2009) translate into diﬀerent time
curves for D2 receptor occupancy in the human brain.
The 300 mg daily dose used in the present study is
at the lower end of the dose interval recommended
for the treatment of schizophrenia, i.e. 150–750 mg for
IR and 400–800 mg for XR (Seroquel
1 Prescribing
Information, 2010a; Seroquel
1 XR Prescribing Infor-
mation, 2010b). As for other CNS drugs, previous
pharmacokinetic studies of quetiapine IR have shown
inter-individual variability in the relationship between
dose and plasma concentration (DeVane & Nemeroﬀ,
2001; Hasselstrom & Linnet, 2004).
In clinical practice, quetiapine IR is predominantly
administered twice-daily for the treatment of schizo-
phrenia and bipolar mania according to approved
labels. However, once-daily dosing of quetiapine IR
has shown eﬃcacy in bipolar depression (Calabrese
et al. 2005). As the primary aim of this study was to
achieve a direct comparison of the XR and IR for-
mulations, IR was administered only once-daily. The
plasma concentration and corresponding D2 receptor
occupancy can therefore not be directly translated
to the more commonly used twice-daily dosing. The
peak D2 receptor occupancy associated with standard
150 mg twice-daily treatment with the IR formulation
would, in all probability, be lower than the receptor
occupancy obtained in the present study.
The dose of quetiapine XR required to occupy 50%
of the D2 receptor was estimated to be 638 mg (con-
tinuous once-daily dosing). The recommended dose of
quetiapine XR for the treatment of schizophrenia (i.e.
400–800 mg) would, according to the same equation,
correspond to 39–56% occupancy of the D2 receptor.
This estimation is in agreement with the literature,
since the average peak D2 receptor occupancy mea-
sured after dosing with 800 mg quetiapine XR has
been reported to be 56% (Mamo et al. 2008).
For typical antipsychotic drugs, it has been sug-
gested that D2 receptor occupancy of at least 65–70%
is required for an antipsychotic eﬀect, and that the
risk of extrapyramidal side-eﬀects (EPS) is high when
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plasma concentration (IR and XR formulations).
D2 receptor occupancy with quetiapine IR and XR 1363D2 receptor occupancy exceeds 80% (Farde et al. 1992;
Kapur et al. 2000a). A therapeutic window of 65–80%
D2 receptor occupancy has therefore been suggested.
In PET studies with recommended doses of the
second-generation antipsychotic drugs, risperidone
and olanzapine, D2 receptor occupancy has been
within this window (Kapur et al. 1999; Nordstro ¨m
et al. 1998; Nyberg et al. 1999; Tauscher et al. 2002).
However, the atypical antipsychotic drug, clozapine,
has an antipsychotic eﬀect at lower D2 receptor occu-
pancy(20–67%),despiteanunsurpassedeﬃcacyinthe
treatment of schizophrenia (Kane, 1989; Nordstro ¨m
et al. 1995). Previous PET studies have shown that
quetiapine induces low to moderate D2 receptor occu-
pancy (29–74% at peak, 0–27% at trough) when given
at clinical doses (Gefvert et al. 1998; Kapur et al. 2000b;
Mamo et al. 2008; Tauscher-Wisniewski et al. 2002).
The results in the present study corroborate these
previous observations. Based on calculations using
equation (2) (see Methods section), 1185 mg quetia-
pine XR would be required to achieve 65% D2 occu-
pancy at peak. It can thus not be excluded that
quetiapine, like clozapine, induces an antipsychotic
eﬀect at low striatal D2 receptor occupancy (for review
see Nord & Farde, 2010). However, whether the anti-
psychotic eﬀect is related to D2 occupancy alone, or if
additional mechanisms are involved remains to be
elucidated.
The Ki,app value can also be used to calculate the
quetiapine dose required to exceed 80% of D2 receptor
occupancy, above which the risk of EPS is increased
(Farde et al. 1992; Kapur et al. 2000a). Interestingly,
quetiapine XR doses exceeding 2550 mg (4rKi,app)
would be needed to reach this level. Thus, during
treatment with clinically recommended doses, it is
unlikely that D2 receptor occupancy reaches the 80%
threshold suggested for EPS. This is in agreement with
clinical studies showing a low incidence of EPS in
quetiapine-treated patients (Baldwin & Scott, 2009;
Weiden, 2007).
A strength of this study is that individual baseline
values of BP were used to calculate D2 receptor occu-
pancy. Using this methodology, errors based on indi-
vidual variability in receptor densities are minimized.
However, a critical experimental condition is that
D2 receptor occupancy is indeed measured at Cmax.A s
the peak is sharp, peak PET measurements with IR are
particularly sensitive to errors if Tmax and the start of
PET measurement are not exactly matched. A com-
parison of the plasma concentration curve with the
time of the peak PET measurement for individual
subjects shows that the PET measurements in most
cases started at Tmax. In one subject the PET measure-
ment started just after Tmax and in another subject PET
measurement started just before Tmax, but the peak
concentrations were reached within the time-frame of
the PET measurements. Peak D2 receptor occupancy
values in these two subjects were 45% and 52%, and
were thus within the range of other assessments.
However, the possibility that D2 receptor occupancy
might have been underestimated in these two subjects
cannot be excluded. Regarding the XR formulation,
peak PET measurements are less sensitive as the time
curve for plasma concentration is more blunted.
Pharmacokinetic studies have demonstrated dose
equivalence of the two formulations based on the
calculated AUC for standardized dosing intervals
(Figueroa et al. 2009). The present pharmacokinetic
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Fig. 5. Estimated D2 dopamine receptor occupancy (%) vs. time for quetiapine IR (left) and XR (right) formulations. The solid
lines describe the occupancy time curve for a typical individual. The grey areas represent the 95% prediction intervals.
1364 M. Nord et al.ﬁndings conﬁrm similar AUC and consistent Ki values
between the formulations (Table 1). However, our
study also demonstrates more pronounced ﬂuctua-
tions in D2 receptor occupancy with quetiapine IR than
XR. It cannot be excluded that this diﬀerence may re-
sult in diﬀerent pharmacodynamics. Indeed, a recent
experimental study comparing quetiapine XR and IR,
titrated from 50 mg up to 300 mg once-daily, in
63 healthy subjects demonstrated that quetiapine XR
produced signiﬁcantly less sedation than quetiapine
IR during the initial treatment phase (Datto et al. 2009).
The ﬁndings in this study might seem discrepant to
the ﬁndings in a previous study of Mamo et al. (2008),
where no statistical diﬀerence in D2 occupancy was
shown between quetiapine IR and XR. An important
diﬀerence between the studies is that quetiapine
IR was given twice-daily in the study of Mamo et al.
whereas we used a once-daily administration. As al-
ready described, the peak occupancy after a twice-
daily administration of quetiapine IR would in all
likelihood be lower than the peak occupancy after the
same dose administered once-daily. The Ki value re-
ceived from our data was similar for both formula-
tions, indicating that the diﬀerence in occupancy
between the formulations depends on diﬀerences in
plasma concentration. As the treatment regimen in the
study by Mamo et al. did not provide any statistically
diﬀerent peak plasma concentrations of quetiapine
IR and XR, this condition could explain the lack of
diﬀerence in the peak occupancy measured.
Conclusion
Central D2 dopamine receptor occupancy diﬀer-
entiates quetiapine IR and XR. The more sustained D2
receptor occupancy after administration of quetiapine
XR vs. IR makes this formulation appropriate for the
once-daily treatment regimen. The ﬁndings in the
present study support the view that quetiapine may
have an antipsychotic eﬀect at moderate and inter-
mediate striatal D2 receptor occupancy. Further stu-
diesare neededto evaluate ifthe antipsychotic eﬀect of
quetiapine depends on D2 receptor occupancy alone
or if, intriguingly, there are additional antipsychotic
mechanisms related to other receptor systems.
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